Liver involvement in neuroblastoma: The memorial sloan-kettering experience supports treatment reduction in young patients

Pediatric Blood and Cancer

Volumn 46, Issue 3, 2006, Pages 278-284

  Kushner, Brian H ^a   Kramer, Kim ^a   LaQuaglia, Michael P ^a   Modak, Shakeel ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Liver metastases; Neuroblastoma; Prognostic markers

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; ISOTRETINOIN; VINCRISTINE;

BONE METASTASIS; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INFANT; LIVER DISEASE; LIVER METASTASIS; MALE; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

BONE MARROW NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LIVER; LIVER NEOPLASMS; MALE; NEUROBLASTOMA; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 32044465011     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20564     Document Type: Review

References (17)

1. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. The Oncologist 2003;8:278-292.
2. Rubie H, Hartman O, Michon J, et al. N-myc gene amplification is a major prognostic factor in localized neuroblastoma: Results of the French NBL 90 Study. J Clin Oncol 1997;15:1171-1182.
3. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 2000;18:1260-1268.
4. Evans AE, Silber JH, Shpilsky A, et al. Successful management of low-stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 1996;14:2405-2410.
5. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-1173.
6. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
7. Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: The Pediatric Oncology Group experience-A Pediatric Oncology Group study. J Clin Oncol 1998;16:2007-2017.
8. Dubois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol/Oncol 1999;21:181-189.
9. Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study. J Clin Oncol 2000;18:477-486.
10. Hero B, Simon T, Horz S, et al. Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis? Med Pediatr Oncol 2000;35:683-687.
11. Schleiermacher G, Rubie H, Hartmann O, et al. Treatment of stage 4s neuroblastoma-report of 10 years' experience of the French Society of Paediatric Oncology (SFOP). Br J Cancer 2003;89:470-476.
12. Kushner BH, O'Reilly RJ, LaQuaglia M, et al. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma. Cancer 1990;66:1095-1100.
13. Cheung N-KV, Kushner BH, LaQuaglia M, et al. N7: A novel multi-modality therapy of high-risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 2000;36:227-230.
14. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic studies: A Children's Cancer Group study. J Clin Oncol 1998;16:1256-1264.
15. Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose (21 Gy) radiotherapy for high-risk neuroblastoma following intensive chemotherapy and surgery. J Clin Oncol 2001;19:2821-2828.
16. George R, London WB, Maris JM, et al. Age as a continuous variable in predicting outcome for neuroblastoma patients with metastatic disease: Impact of tumor biological features. Proc Am Soc Clin Oncol 2003;22:799. (Abstract).
17. Schmidt ML, Lal A, Seeger R, et al. Favorable prognosis for patients ages 12-18 months with stage 4 MYCN-nonamplified neuroblastoma. Proc Am Soc Clin Oncol 2003;22:800. (Abstract).